By 2030, it is anticipated that the Singapore Dermatology drugs market will reach a value of $xx Mn from $20.4 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as GreenCare Pharmaceuticals, Sawkare, and Kim Han Laboratories. The market is driven by Tele-dermatology, awareness about dermatological health, and the availability of generic drugs. The dermatology drug market in Singapore is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.
By 2030, it is anticipated that the Singapore Dermatology drugs market will reach a value of $xx Mn from $20.4 Mn in 2022, growing at a CAGR of xx% during 2022-2030.
In order to provide dermatology services to the local population, the National Skin Centre (NSC) and National Healthcare Group Polyclinics (NHGP) in Singapore introduced Tele-DERM in 2016. In Singapore, in all age groups, dermatitis (33.3%), acne vulgaris (8.3%), and viral skin diseases (7.5%) were the three most common dermatoses. Dermatitis (37.7% of all skin conditions), viral skin diseases (6.2%), and fungal skin diseases (4.3%) were the three most prevalent skin conditions in elderly people in Singapore.
Singapore offers comprehensive coverage for all of its citizens and is ranked 12th in the world for healthcare innovation in 2021. It spends the most per capita on healthcare among its ASEAN counterparts, and given the aging population and demographic changes in the nation, this amount is predicted to increase more quickly than GDP. Singapore's government spent 4.1% of its GDP on healthcare in 2019.
Market Growth Drivers
Given that many Singaporeans still choose not to visit clinics or hospitals, the number of teledermatology providers and the demand for their services both significantly increased and remain high. Teledermatology may become a more significant care model due to the aging population in the years to come, and COVID-19 has just accelerated the shift.
Market Restraints
The demand for name-brand dermatology drugs may be constrained by the expanding availability of generic medications. The use of complementary therapies like herbal or conventional medicines may affect the market for dermatology medications. These factors may discourage new players from entering the market.
Key Players
The Health Sciences Authority (HSA) is the regulatory body in Singapore in charge of overseeing dermatology drug approval and regulation. As Singapore's national health product regulatory body, the HSA is in charge of ensuring the efficacy, safety, and quality of all pharmaceuticals, including those used to treat skin conditions.
Singapore's Central Provident Fund (CPF), the nation's mandatory savings program for those in the labor force, pays for dermatology medication reimbursement. All Singaporeans have access to MediShield Life coverage through CPF, which is a fundamental health insurance program. Numerous medical procedures are covered by MediShield Life, including medications for some skin conditions prescribed by dermatologists. There are private health insurance plans that cover dermatology medications in Singapore in addition to MediShield Life. These policies frequently provide more thorough coverage than MediShield Life and might pay for a wider variety of medications and treatments.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
The Dermatology Drugs Market is segmented as mentioned below
By Disease (Revenue, USD Billion):
By Route Of Administration (Revenue, USD Billion):
By Distribution Channel (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.